These updates are expected to shift prescribing practices by making SGLT-2 inhibitors a first-line therapy for HFpEF to reduce HF hospitalizations, improve symptoms, and enhance the quality of life for HFpEF patients. The gene discussed is SLC5A2; the disease is hydrops fetalis.